evYsio Medical Devices ULC, a private Canadian company, announced
that a French court has ruled in its favor in a patent infringement
lawsuit it commenced against affiliates of Abbott Laboratories
(NYSE:ABT). In particular, the Tribunal de Grande Instance de Paris
ruled that Abbott's Xience(TM) V drug-eluting coronary stent infringes
evYsio's European Patent No. EP-B- 0 888 093 and has awarded evYsio
the right to enjoin the importation, offering for sale, or sale of the
Xience(TM) V stent in France. This injunction is now in effect. Abbott
may appeal the decision.
evYsio and/or Medtronic, Inc. (NYSE:MDT) have commenced
infringement lawsuits in other countries alleging that Abbott's
MULTI-LINK Vision(R) and/or Xience(TM) V coronary stents infringe
patents under exclusive worldwide license to Medtronic from evYsio,
including in the United States, Ireland, the United Kingdom, and
Germany.
Background on evYsio
evYsio Medical Devices ULC is a private, Vancouver-based developer
of vascular medical products. It develops lesion-specific stents and
special medical devices for use in the fields of interventional
cardiology, radiology and endovascular medicine.
